Medical Health Cluster

coronavirus

New-Onset Long COVID in Adults Less Likely After Reinfection

New findings suggest that the risk of developing long COVID after being reinfected is less for adults but is similar for children. The likelihood of adults (aged 16 and over) self-reporting new-onset long COVID after a second infection with coronavirus (COVID-19) is lower than when compared with a first infection, […]

Read More

SARS-CoV-2 viral load and shedding kinetics

Abstract SARS-CoV-2 viral load and detection of infectious virus in the respiratory tract are the two key parameters for estimating infectiousness. As shedding of infectious virus is required for onward transmission, understanding shedding characteristics is relevant for public health interventions. Viral shedding is influenced by biological characteristics of the virus, […]

Read More

Coronavirus (COVID-19) Update: FDA Approves First COVID-19 Treatment for Young Children

Today, the U.S. Food and Drug Administration expanded the approval of the COVID-19 treatment Veklury (remdesivir) to include pediatric patients 28 days of age and older weighing at least 3 kilograms (about 7 pounds) with positive results of direct SARS-CoV-2 viral testing, who are: Hospitalized, or Not hospitalized and have […]

Read More

Reinfection Rates Among Patients Who Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study

Background Protection afforded from prior disease among patients with coronavirus disease 2019 (COVID-19) infection is unknown. If infection provides substantial long-lasting immunity, it may be appropriate to reconsider vaccination distribution. Methods This retrospective cohort study of 1 health system included 150,325 patients tested for COVID-19 infection via polymerase chain reaction […]

Read More

Estudios ofrecen más evidencia de que la pandemia de coronavirus comenzó en animales, en el mercado de Wuhan

Dos estudios preliminares publicados este sábado ofrecen más evidencia de que el coronavirus se originó en animales y se propagó a los humanos a fines de 2019 en el mercado de mariscos de Huanan, en Wuhan, China. Uno de los estudios –ninguno de los cuales ha sido revisado por pares ni […]

Read More

Ensayada una vacuna de mRNA liofilizado

El Shenzhen Rhegen Biotechnology Co. Ltd de la República Popular China ha publicado en preprint los resultados de una vacuna frente a la COVID-19 de ARN mensajero en forma liofilizada termoestable envuelto en nanopartículas lipídicas que podría almacenarse a temperatura ambiente durante largos periodos de tiempo. En concreto, presenta resultados de tres vacunas dirigidas […]

Read More

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022

What is already known about this topic? In preauthorization trials, adverse reactions were reported less frequently following a homologous COVID-19 mRNA vaccine booster dose than after receipt of the second primary dose. What is added by this report? Review of surveillance data found that local and systemic reactions were less […]

Read More

La variante ómicron ‘encontrará a casi todos’, dice Fauci, pero a las personas vacunadas les irá mejor

A medida que la variante ómicron del nuevo coronavirus se propaga como un reguero de pólvora en Estados Unidos, es probable que casi todos estén expuestos a la cepa, pero a las personas vacunadas les irá mejor, dijo el martes el principal experto en enfermedades infecciosas del país. “Ómicron, con su grado […]

Read More

Mayo expert clears up confusion about COVID-19 boosters

The Centers for Disease Control and Prevention (CDC) has updated its recommendations for the Pfizer COVID-19 vaccine to expand the use of a single booster dose to 12- to 15-year-olds. The Food and Drug Administration amended its emergency use authorization earlier this week. “Everyone at age 12 and up is approved for a booster after they’ve […]

Read More

THE DREAM VACCINE; Why stop at just SARS-CoV-2? Vaccines in development aim to protect against many coronaviruses at once

Why stop at just SARS-CoV-2? Vaccines in development aim to protect against many coronaviruses at once. In 2017, three leading vaccine researchers submitted a grant application with an ambitious goal. At the time, no one had proved a vaccine could stop even a single beta coronavirus—the notorious viral group then […]

Read More